{
    "clinical_study": {
        "@rank": "136135", 
        "arm_group": [
            {
                "arm_group_label": "L-Methylfolate", 
                "arm_group_type": "Experimental", 
                "description": "15 mg of L-Methylfolate (Deplin\u00ae) daily for 12 weeks as a supplement to OROS-Methylphenidate."
            }, 
            {
                "arm_group_label": "Placebo (for L-Methylfolate)", 
                "arm_group_type": "Placebo Comparator", 
                "description": "15 mg matched placebo comparator, with open-label OROS-Methylphenidate"
            }
        ], 
        "brief_summary": {
            "textblock": "This pilot study seeks to evaluate initial evidence for efficacy and tolerability of\n      L-methylfolate supplementation to OROS-Methylphenidate pharmacotherapy in treating Attention\n      Deficit Hyperactivity Disorder (ADHD) and associated symptoms in adults with ADHD. The\n      investigators will conduct a 12-week double-blind randomized placebo-controlled trial with\n      L-methylfolate supplementing open-label OROS-Methylphenidate (OROS-MPH) treatment. The\n      investigators propose to examine 40 adult (ages 18-55) subjects satisfying the DSM-IV\n      diagnostic criteria for ADHD."
        }, 
        "brief_title": "L-methylfolate Supplementation to OROS-Methylphenidate Pharmacotherapy in ADHD Adults", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Attention Deficit Hyperactivity Disorder", 
        "condition_browse": {
            "mesh_term": [
                "Attention Deficit Disorder with Hyperactivity", 
                "Hyperkinesis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male or female adults ages 18-55 years of age.\n\n          2. A diagnosis of childhood onset ADHD, meeting all but the age of onset criteria\n             according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth\n             Edition (DSM-IV),  based on clinical assessment.  Childhood onset will be defined\n             according to established research criteria, requiring onset of two symptoms of\n             inattentive or of impulsive/hyperactive traits by the age of 12 22.\n\n          3. A score of 24 or more on the Adult ADHD Investigator Symptom Report Scale (AISRS).\n\n        Exclusion Criteria:\n\n          1. A history of non-response or intolerance to methylphenidate at adequate doses as\n             determined by the clinician.\n\n          2. A history of intolerance to L-methylfolate supplementation.\n\n          3. Pregnant or nursing females.\n\n          4. Serious, unstable medical illness including hepatic, renal, gastroenterological,\n             respiratory, cardiovascular, endocrinologic (thyroid), neurologic (seizure),\n             immunologic, or hematologic disease.\n\n          5. Glaucoma.\n\n          6. Clinically unstable psychiatric conditions including suicidality, homicidality,\n             bipolar disorder, psychosis, history of or current marked anxiety, tension or\n             agitation potentially exacerbated by a stimulant, or lifetime history of any other\n             clinically serious condition potentially exacerbated by a stimulant, such as mania or\n             psychosis.\n\n          7. Tics or a family history or diagnosis of Tourette's syndrome.\n\n          8. Current (within 3 months) DSM-IV criteria for abuse or dependence with any\n             psychoactive substance other than nicotine.\n\n          9. Multiple adverse drug reactions.\n\n         10. Any other concomitant medication with primarily central nervous system activity other\n             than specified in Concomitant Medication portion of the protocol.\n\n         11. Current use of MAO Inhibitor or use within the past two weeks.\n\n         12. Investigator and his/her immediate family; defined as the investigator's spouse,\n             parent, child, grandparent, or grandchild.\n\n         13. Use of supplemental folic acid greater than 400 mcg per day, L-methylfolate, or\n             Omega-3 Fatty Acids greater than 800 mcg per day within two weeks prior to the\n             baseline study visit."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01853280", 
            "org_study_id": "2012-P-000379"
        }, 
        "intervention": [
            {
                "arm_group_label": "L-Methylfolate", 
                "description": "15mg/day L-methylfolate.", 
                "intervention_name": "L-methylfolate", 
                "intervention_type": "Drug", 
                "other_name": "Deplin\u00ae"
            }, 
            {
                "arm_group_label": [
                    "L-Methylfolate", 
                    "Placebo (for L-Methylfolate)"
                ], 
                "description": "All subjects will be treated with open-label OROS-MPH", 
                "intervention_name": "OROS-Methylphenidate", 
                "intervention_type": "Drug", 
                "other_name": "Concerta\u00ae"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Methylphenidate"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "ADHD", 
            "Attention Deficit Hyperactivity Disorder", 
            "Deplin", 
            "L-methylfolate", 
            "Natural Treatments", 
            "Medical Food"
        ], 
        "lastchanged_date": "May 28, 2014", 
        "location": {
            "contact": {
                "email": "rgrossman1@mgh.harvard.edu", 
                "last_name": "Rebecca Grossman", 
                "phone": "617-643-1432"
            }, 
            "facility": {
                "address": {
                    "city": "Boston", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "02114"
                }, 
                "name": "Massachusetts General Hospital"
            }, 
            "investigator": {
                "last_name": "Craig B Surman, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "L-methylfolate Supplementation to OROS-Methylphenidate Pharmacotherapy in ADHD Adults: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial", 
        "overall_contact": {
            "email": "rgrossman1@mgh.harvard.edu", 
            "last_name": "Rebecca Grossman, B.A.", 
            "phone": "617-643-1432"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Each of the individual DSM-IV symptoms of ADHD is rated 0 to 3 on a scale of severity.", 
            "measure": "Adult ADHD Investigator Symptom Rating Scale", 
            "safety_issue": "No", 
            "time_frame": "Assessed at each visit from baseline to study completion (12 weeks)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01853280"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Massachusetts General Hospital", 
            "investigator_full_name": "Craig B. Surman, MD", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Massachusetts General Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "Pamlab, Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Massachusetts General Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}